BioImagene and Scimagix Merge to Provide
Comprehensive Image Analysis and Informatics
Solutions
SAN JOSE, Calif.--(BUSINESS WIRE)--Nov. 10,
2004--BioImagene and Scimagix are pleased to
announce their merger. The combination of BioImagene's
core competency in image analysis with Scimagix'
image management and data mining technology address
major pain-points in the discovery and histo-pathology
markets. Together, they will provide complete,
integrated solutions for gels, cells and tissues,
from initial analysis to data mining and post-hoc
analysis. This comprehensive, web-enabled suite
of products is a major step toward the companies'
joint goal of enabling digital discovery and
histo-pathology.
"Scimagix provides a very good strategic
fit with BioImagene. Together we have a critical
mass of technology, products, customers and partners
that positions us as a leading player in the
marketplace," said Mohan Uttarwar, President
and CEO of BioImagene, and of the combined company
going forward.
"This is a major step toward the fulfillment
of image informatics' promise of advancing science,
technology and health care. BioImagene and Scimagix
together will extend and amplify these benefits.
The combined offerings will be very valuable
to our customers. They will facilitate a seamless
work flow resulting in higher through-put and
higher productivity, translating into improved
discovery and tissue analysis processes and outcomes," said
Robert Dunkle, President of Scimagix.
And customers of both BioImagene and Scimagix
agree. "I'm very encouraged about the merging
of these technology platforms," said Bruce
Keyt, VP of Preclinical Development at Abgenix,
and a customer of both companies. "It relieves
me of concerns regarding reinventing the wheel.
We won't have to worry about integration challenges
when we use Scimagix' storage and data mining
tools for the data we get from BioImagene's quantitation
and analysis. This will broaden our information
transfer technology. We've worked a great deal
with both Scimagix and BioImagene. These technologies
working together will provide very powerful tools
for evaluating therapeutic antibodies at Abgenix."
The combined company will provide all existing
customers with ongoing support, maintenance and
further development of both companies' product
lines.
About Scimagix Inc.
Scimagix™ Inc., based in San Mateo, Calif.,
is the leading provider of image informatics
solutions for pharmaceutical research and development
(R&D). Its flagship SIMS™ (Scientific
Image Management System) platform is the first
database management system designed to optimize
the use of images generated during drug R&D.
The Oracle®/Web-based software system is
an open architecture platform that enables group-
to enterprise-wide image management, providing
researchers with a comprehensive and searchable
database of image data. The Scimagix Application
Suite supports high throughput analysis and mining
of image data with its proprietary visual content
search technology. This innovative technology
dramatically increases the accuracy and productivity
of R&D processes by enabling users to select
and search based on a specific region of an image,
to easily retrieve image sets from diverse experiments
based on specific search parameters, to identify
correlations, and to gain access to expert data
across laboratories and the corporation. Scimagix
presently serves eight of the top 15 pharmaceutical
companies, including Pfizer Global R&D and
Eli Lilly & Co.
About BioImagene, Inc.
BioImagene provides sophisticated bio-image analysis
products built on iHarness, its patent-pending
technology platform. BioImagene's products
allow physicians and researchers to analyze
and interpret images with far greater speed
and consistency. The data management systems
of BioImagene's technology facilitate communication
and collaboration, improving the standard of
patient care and increasing the speed of discovery.
Its scalable digital image analysis solutions
have been embraced by histopathologists, industry
and researchers alike.
